Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12078989 | 0.95 | KMT2A (0.50) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL21737963 | 0.95 | KMT2A (0.50) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL12078991 | 0.95 | KMT2A (0.50) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL21797227 | 0.95 | KMT2A (0.50) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL23583190 | 0.79 | FUCA1 (0.50) | KDM4EALDH1A1KMT2AMEN1S1PR1 | |
| SCHEMBL9177398 | 0.75 | CYP2D6 (0.42) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL38609 | 0.74 | GRIN2B (0.42) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL15908954 | 0.74 | GRIN2B (0.42) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL37731 | 0.74 | GRIN2B (0.42) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL9838655 | 0.73 | ALDH1A1 (0.42) | KDM4EALDH1A1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | KDM4E 413/4885ALDH1A1 2000/4885KMT2A 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.